Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects.
Identifieur interne : 000572 ( Ncbi/Merge ); précédent : 000571; suivant : 000573Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects.
Auteurs : C. Corbe [France] ; F. Arnaud ; Y. Brault ; C. Janiak-BolzingerSource :
- Journal of neurology [ 0340-5354 ] ; 1992.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Piribedil.
- chemical , deficiency : Dopamine.
- drug effects : Contrast Sensitivity, Retina.
- chemical , pharmacology : Piribedil.
- physiology : Aging, Contrast Sensitivity, Space Perception.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Dopamine acts as a neuromodulator in the retina. Dopaminergic deficiency of any origin, as observed in elderly subjects, is associated with altered visual performances, and more specifically with altered perception of contrasts. The goal of this study was to compare contrast vision in elderly subjects and young subjects (first phase, n = 20), then to compare this function in elderly subjects before and after 3 months of treatment with a dopaminergic agonist, piribedil (Trivastal 50 mg LP), administered once daily (second phase, n = 20). The perception of contrast was analysed using a test measuring sensitivity to colour contrast yielding threshold values for sensitivity to contrast in eight spatial frequencies and three colours (red, green, blue) and in two directions (horizontal and vertical). The results of the first phase of the study demonstrated that elderly subjects showed a decrease in contrast perception in comparison with young subjects, primarily in the high frequency range, and over the full range of stimulation for direction and colour. In the second phase, elderly subjects, in comparison with young subjects, showed altered visual contrast, again in the high frequency range, but also in the low frequency range for horizontal simulation with red and blue. After 3 months of treatment with piribedil the mean contrast sensitivity threshold, over the entire frequency range, had significantly increased (P less than 0.05) for all stimulations, apart for red in the vertical direction. These results underline the value of treatment with a dopaminergic agonist, piribedil in visual disturbances in patients with dopaminergic deficiency (Parkinson patients or elderly subjects).
PubMed: 1634908
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001777
- to stream PubMed, to step Curation: 001736
- to stream PubMed, to step Checkpoint: 001736
Links to Exploration step
pubmed:1634908Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects.</title><author><name sortKey="Corbe, C" sort="Corbe, C" uniqKey="Corbe C" first="C" last="Corbe">C. Corbe</name><affiliation wicri:level="3"><nlm:affiliation>Service d'Ophtalmologie, C.P.E.M.P.N., Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Ophtalmologie, C.P.E.M.P.N., Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Arnaud, F" sort="Arnaud, F" uniqKey="Arnaud F" first="F" last="Arnaud">F. Arnaud</name></author><author><name sortKey="Brault, Y" sort="Brault, Y" uniqKey="Brault Y" first="Y" last="Brault">Y. Brault</name></author><author><name sortKey="Janiak Bolzinger, C" sort="Janiak Bolzinger, C" uniqKey="Janiak Bolzinger C" first="C" last="Janiak-Bolzinger">C. Janiak-Bolzinger</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1634908</idno><idno type="pmid">1634908</idno><idno type="wicri:Area/PubMed/Corpus">001777</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001777</idno><idno type="wicri:Area/PubMed/Curation">001736</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001736</idno><idno type="wicri:Area/PubMed/Checkpoint">001736</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001736</idno><idno type="wicri:Area/Ncbi/Merge">000572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects.</title><author><name sortKey="Corbe, C" sort="Corbe, C" uniqKey="Corbe C" first="C" last="Corbe">C. Corbe</name><affiliation wicri:level="3"><nlm:affiliation>Service d'Ophtalmologie, C.P.E.M.P.N., Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Ophtalmologie, C.P.E.M.P.N., Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Arnaud, F" sort="Arnaud, F" uniqKey="Arnaud F" first="F" last="Arnaud">F. Arnaud</name></author><author><name sortKey="Brault, Y" sort="Brault, Y" uniqKey="Brault Y" first="Y" last="Brault">Y. Brault</name></author><author><name sortKey="Janiak Bolzinger, C" sort="Janiak Bolzinger, C" uniqKey="Janiak Bolzinger C" first="C" last="Janiak-Bolzinger">C. Janiak-Bolzinger</name></author></analytic><series><title level="j">Journal of neurology</title><idno type="ISSN">0340-5354</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aging (physiology)</term><term>Contrast Sensitivity (drug effects)</term><term>Contrast Sensitivity (physiology)</term><term>Dopamine (deficiency)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Piribedil (adverse effects)</term><term>Piribedil (pharmacology)</term><term>Retina (drug effects)</term><term>Space Perception (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Contrast Sensitivity</term><term>Retina</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Piribedil</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Aging</term><term>Contrast Sensitivity</term><term>Space Perception</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine acts as a neuromodulator in the retina. Dopaminergic deficiency of any origin, as observed in elderly subjects, is associated with altered visual performances, and more specifically with altered perception of contrasts. The goal of this study was to compare contrast vision in elderly subjects and young subjects (first phase, n = 20), then to compare this function in elderly subjects before and after 3 months of treatment with a dopaminergic agonist, piribedil (Trivastal 50 mg LP), administered once daily (second phase, n = 20). The perception of contrast was analysed using a test measuring sensitivity to colour contrast yielding threshold values for sensitivity to contrast in eight spatial frequencies and three colours (red, green, blue) and in two directions (horizontal and vertical). The results of the first phase of the study demonstrated that elderly subjects showed a decrease in contrast perception in comparison with young subjects, primarily in the high frequency range, and over the full range of stimulation for direction and colour. In the second phase, elderly subjects, in comparison with young subjects, showed altered visual contrast, again in the high frequency range, but also in the low frequency range for horizontal simulation with red and blue. After 3 months of treatment with piribedil the mean contrast sensitivity threshold, over the entire frequency range, had significantly increased (P less than 0.05) for all stimulations, apart for red in the vertical direction. These results underline the value of treatment with a dopaminergic agonist, piribedil in visual disturbances in patients with dopaminergic deficiency (Parkinson patients or elderly subjects).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1634908</PMID><DateCreated><Year>1992</Year><Month>08</Month><Day>25</Day></DateCreated><DateCompleted><Year>1992</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-5354</ISSN><JournalIssue CitedMedium="Print"><Volume>239 Suppl 1</Volume><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects.</ArticleTitle><Pagination><MedlinePgn>S22-7</MedlinePgn></Pagination><Abstract><AbstractText>Dopamine acts as a neuromodulator in the retina. Dopaminergic deficiency of any origin, as observed in elderly subjects, is associated with altered visual performances, and more specifically with altered perception of contrasts. The goal of this study was to compare contrast vision in elderly subjects and young subjects (first phase, n = 20), then to compare this function in elderly subjects before and after 3 months of treatment with a dopaminergic agonist, piribedil (Trivastal 50 mg LP), administered once daily (second phase, n = 20). The perception of contrast was analysed using a test measuring sensitivity to colour contrast yielding threshold values for sensitivity to contrast in eight spatial frequencies and three colours (red, green, blue) and in two directions (horizontal and vertical). The results of the first phase of the study demonstrated that elderly subjects showed a decrease in contrast perception in comparison with young subjects, primarily in the high frequency range, and over the full range of stimulation for direction and colour. In the second phase, elderly subjects, in comparison with young subjects, showed altered visual contrast, again in the high frequency range, but also in the low frequency range for horizontal simulation with red and blue. After 3 months of treatment with piribedil the mean contrast sensitivity threshold, over the entire frequency range, had significantly increased (P less than 0.05) for all stimulations, apart for red in the vertical direction. These results underline the value of treatment with a dopaminergic agonist, piribedil in visual disturbances in patients with dopaminergic deficiency (Parkinson patients or elderly subjects).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corbe</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service d'Ophtalmologie, C.P.E.M.P.N., Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnaud</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Brault</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Janiak-Bolzinger</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>DO22K1PRDJ</RegistryNumber><NameOfSubstance UI="D010891">Piribedil</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015350" MajorTopicYN="N">Contrast Sensitivity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010891" MajorTopicYN="N">Piribedil</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1634908</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Arnaud, F" sort="Arnaud, F" uniqKey="Arnaud F" first="F" last="Arnaud">F. Arnaud</name><name sortKey="Brault, Y" sort="Brault, Y" uniqKey="Brault Y" first="Y" last="Brault">Y. Brault</name><name sortKey="Janiak Bolzinger, C" sort="Janiak Bolzinger, C" uniqKey="Janiak Bolzinger C" first="C" last="Janiak-Bolzinger">C. Janiak-Bolzinger</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Corbe, C" sort="Corbe, C" uniqKey="Corbe C" first="C" last="Corbe">C. Corbe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000572 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000572 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:1634908
|texte= Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:1634908" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |